Patents by Inventor Arthur D. Riggs
Arthur D. Riggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083998Abstract: Disclosed is a method of preventing or treating acute GVHD (aGVHD) such as gut aGVHD, steroid-resistant aGVHD, and steroid-resistant gut aGVHD in a subject receiving a hematopoietic cell transplantation (HCT) or autoimmune colitis by administering to the subject an effective amount of an anti-IL-22 antibody, an anti-IL-6 antibody, donor-type CX3CR1hi MNPs, donor-type NK cells, a ceacam-1 antagonist, an anti-Gr-1 antibody, or a combination thereof.Type: ApplicationFiled: January 3, 2022Publication date: March 14, 2024Applicant: CITY OF HOPEInventors: Defu ZENG, Qingxiao SONG, Arthur D. RIGGS
-
Publication number: 20240025990Abstract: Disclosed is a method of preventing or treating GVHD while preserving GVL activity in a subject receiving a hematopoietic cell transplantation (HCT) by administering to the subject an effective amount of an anti-IL-2 antibody such as an anti-IL-2-JES6 antibody.Type: ApplicationFiled: December 1, 2021Publication date: January 25, 2024Applicant: CITY OF HOPEInventors: Defu ZENG, Arthur D. RIGGS, Qingxiao SONG
-
Publication number: 20210214692Abstract: Disclosed herein are methods for reprogramming a somatic cell into a pluripotent stem cell by contacting the somatic cell with one or more antifolate agents, with or without methionine, in vitro for a period of time sufficient to reprogramming the somatic cell and selecting and growing the cells that express one or more stem cell markers. Also disclosed are induced pluripotent stem cells obtained from somatic cells.Type: ApplicationFiled: November 17, 2020Publication date: July 15, 2021Applicant: CITY OF HOPEInventors: Arthur D. RIGGS, Avinash C. SRIVASTAVA, Timothy R. O'CONNOR
-
Patent number: 7923221Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.Type: GrantFiled: April 13, 1995Date of Patent: April 12, 2011Assignees: Genentech, Inc, City of HopeInventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
-
Patent number: 7238480Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or near its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.Type: GrantFiled: March 12, 2004Date of Patent: July 3, 2007Assignee: City of HopeInventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
-
Patent number: 7083926Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.Type: GrantFiled: May 12, 2003Date of Patent: August 1, 2006Assignee: City of HopeInventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
-
Patent number: 7033763Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3?-deoxynucleotide at its 3? terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3? end for the rare allele but has a mismatch at or rear its 3? terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3? specific sequence as far as 16 nucleotides away from the 3? terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.Type: GrantFiled: May 9, 2003Date of Patent: April 25, 2006Assignee: City of HopeInventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
-
Publication number: 20040009515Abstract: A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3′-deoxynucleotide at its 3′ terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3′ end for the rare allele but has a mismatch at or rear its 3′ terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3′ specific sequence as far as 16 nucleotides away from the 3′ terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele.Type: ApplicationFiled: May 9, 2003Publication date: January 15, 2004Inventors: Qiang Liu, Steve S. Sommer, Arthur D. Riggs
-
Publication number: 20030228615Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.Type: ApplicationFiled: May 12, 2003Publication date: December 11, 2003Inventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
-
Patent number: 6562570Abstract: A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined ribozymes or DNAzymes, or with a semi-random ribozyme or DNAzyme library, in a cell extract containing endogenous RNA-binding proteins, or in a medium which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, ribozyme or DNAzyme which is complementary to an accessisble site in the target RNA hybridizes to that site and the RNA is cleaved at that site. Reverse transcription can be used to generate a first strand DNA from the RNA cleavage product, and terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) can be used to identify sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred.Type: GrantFiled: March 28, 2000Date of Patent: May 13, 2003Assignee: City of HopeInventors: John J. Rossi, Michaela Scherr, Arthur D. Riggs
-
Patent number: 6331415Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.Type: GrantFiled: June 10, 1988Date of Patent: December 18, 2001Assignee: Genentech, Inc.Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
-
Patent number: 6242567Abstract: Disclosed are amino acid sequences of the late 64 kilodalton protein of human cytomegalovirus (HCMVgp64), useful in diagnosing and preventing HCMV infections.Type: GrantFiled: March 22, 1995Date of Patent: June 5, 2001Assignee: City of HopeInventors: Hema Pande, Arthur D. Riggs, John A. Zaia, Brian R. Clark
-
Patent number: 6133433Abstract: A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one (721) nucleotides. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The major late protein of human cytomegalovirus (HCMVgp64) also reacts with T-lymphocytes of an individual after natural infection of that individual with human cytomegalovirus. Thus, the HCMVgp64 protein may be used as a vaccine to prevent HCMV infection.Type: GrantFiled: June 6, 1995Date of Patent: October 17, 2000Assignee: City of HopeInventors: Hema Pande, Arthur D. Riggs, John A. Zaia, Brian R. Clark
-
Patent number: 5583013Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.Type: GrantFiled: May 2, 1995Date of Patent: December 10, 1996Assignee: Genentech, Inc.Inventors: Keiichi Itakura, Arthur D. Riggs
-
Patent number: 5420020Abstract: 1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.Type: GrantFiled: July 25, 1994Date of Patent: May 30, 1995Assignee: Genentech, Inc.Inventor: Arthur D. Riggs
-
Patent number: 5270183Abstract: The present invention provides an apparatus and method for the amplification of a particular sequence(s) of DNA in a sample using polymerased chain reaction. The method of the present invention involves the injection of a reaction mixture into a stream of carrier fluid. The carrier fluid then passes through a plurality of temperature zones in which the polymerase chain reactions take place. The method of the present invention allows the sequential processing of a number of samples.Type: GrantFiled: February 8, 1991Date of Patent: December 14, 1993Assignee: Beckman Research Institute of the City of HopeInventors: John M. Corbett, Kenneth C. Reed, Arthur D. Riggs
-
Patent number: 5221619Abstract: The Specification discloses:1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA;2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.Type: GrantFiled: January 15, 1992Date of Patent: June 22, 1993Assignee: Genentech, Inc.Inventors: Keiichi Itakura, Arthur D. Riggs
-
Patent number: 5081235Abstract: A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.Type: GrantFiled: July 26, 1989Date of Patent: January 14, 1992Assignee: City of HopeInventors: John E. Shively, Arthur D. Riggs, Michael Neumaier
-
Patent number: 5075431Abstract: A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.Type: GrantFiled: March 26, 1991Date of Patent: December 24, 1991Assignee: City of HopeInventors: John E. Shively, Arthur D. Riggs, Michael Neumaier
-
Patent number: 5075213Abstract: A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one 721) nucleotides. The probe may be labelled as by radioactivity. The probe has been used to screen DNA fragments constituting a subgenomic library of human cytomegalovirus DNA to obtain DNA fragments coding for the major late protein of human cytomegalovirus. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The viral DNA can be used as whole HCMV DNA or as fragments formed by digesting the human cytomegalovirus DNA with a restriction endonuclease such as one of the restriction endonucleases EcoRI, BamHI, XbaI, HindIII and PrtI.Type: GrantFiled: June 20, 1990Date of Patent: December 24, 1991Assignee: City of HopeInventors: Hema Pande, Arthur D. Riggs, John A. Zaia